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Abstract Tetanus toxin (TeTx) modifies Na+-dependent, high-
affinity 5-hydroxytryptamine (5-HT, serotonin) uptake in a
synaptosomal-enriched P2 fraction from rat brain. The effect
corresponds to a rapid and non-competitive uptake inhibition,
and it is preceded by induction of phospholipase C (PLC) activity
and translocation and down-regulation of the classical protein
kinase C (PKC-K, -L and -Q) isoforms. The effects on serotonin
transport and on cPKC activation were similar to the effects
exhibited by phorbol ester 12-O-tetradecanoylphorbol 13-acetate
(TPA). Moreover, after treatment with TeTx, an increase in Ser-
and Tyr-specific phosphorylation was found. Activation of PKC
by both TeTx and TPA results in a loss of transport capacity and
serotonin transporter (SERT) phosphorylation, which are
abolished by coapplication of the specific PKC inhibitor
bisindolylmaleimide-1. Since a specific PLCQ1 phosphorylation
prior to TeTx’s inducing SERT phosphorylation was found, the
studies suggest that part of the action of TeTx consists of
modifying the signal cascade initiated in tyrosine kinase
receptors on nerve tissue previous to its cellular internalization,
resulting in transporter phosphorylation. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Tetanus toxin (TeTx) is produced by the bacilli Clostridium
tetani and is the protein responsible for producing a deadly
syndrome in humans, tetanus disease. Like other neurotoxins,
the active holotoxin is comprised of two fragments, the heavy
(H, 100 kDa) and light (L, 50 kDa) chains, held together by a
disul¢de bond [1]. The 50-kDa C-terminal domain of the H-
chain would be involved in the binding and internalization of
this toxin in neurons [2]; the 50-kDa N-terminal portion of
the H-chain would be involved in the translocation of the L-
chain in the cytosol. L-TeTx is a zinc-endoprotease, which
speci¢cally cleaves synaptobrevin via a process independent
of synaptic activity [3,4].
The action of TeTx is completely neurospeci¢c. Binding to
the plasma membranes is essential for development of spastic
paralysis. Polysyalogangliosides [5] and glycoproteins [6] have
been proposed as candidate receptors. Nevertheless, e¡orts to
¢nd such protein receptors have been futile.
Not all of the clinical symptoms of tetanus intoxication can
be ascribed to the inhibition of vesicular synaptic secretion.
Certain symptoms such as insomnia, hyperactivity, hyperther-
mia, etc., seem to suggest the implication of di¡erent mecha-
nisms, di¡erent neurons, and di¡erent areas of the CNS. Re-
cently, it was demonstrated that TeTx can partially block
neurotransmitter release by stimulating a Ca2-dependent
transglutaminase activity [7]. TeTx also induces protein kinase
C (PKC) translocation, even before classical tetanus symp-
toms are evident [8,9]. Finally, it has been demonstrated
that TeTx blocks Na-dependent 5-hydroxytryptamine (sero-
tonin, 5-HT) uptake in rat-brain synaptosomes [10,11]. This
inhibitory e¡ect has also been studied on other transmitters,
however, only minor or no e¡ects have been observed [12].
Serotonin transporter (SERT) is the sole molecule respon-
sible for extracellular 5-HT transport, coupling uptake to the
in£ux of Na ion down the concentration gradient [13]. PKC
has been implicated as a regulator of SERT activity. Activa-
tors of PKC, such as phorbol esters, induce the phosphoryla-
tion of SERT in Ser/Thr residues responsible for the re-uptake
inhibition [14]. Our group has previously demonstrated that
TeTx, or its HC-fragment, inhibits the [3H]5-HT uptake in rat-
brain synaptosomes. This inhibitory action is independent of
the metalloprotease activity of the neurotoxin contained in the
L-chain, and its potency is two or three orders of magnitude
greater than the serotonin selective re-uptake inhibitors
[10,11].
In the present work, it shall be demonstrated whether or
not the phospholipase C activity and PKC regulation, found
after treatment with TeTx [9], belong to a transduction mech-
anism responsible for the inhibition of the serotonin transport
via carrier phosphorylation.
2. Materials and methods
2.1. Materials
TeTx was provided by List Biological Laboratories, Inc. (Campbell,
CA, USA). Tissue-culture-grade myo-inositol, 5-HT, carbachol, 12-O-
tetradecanoylphorbol 13-acetate (TPA) were from Sigma Chemical
(St. Louis, MO, USA). myo-[2-3H]Inositol (55 Ci/mmol) was from
NEN Research (Boston, MA, USA). 5-[1,2-3H]Hydroxytryptamine
(34 Ci/mmol) was from Amersham International (Buckinghamshire,
UK). Nerve growth factor (NGF) was supplied by Alomone Labs.
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(Jerusalem, Israel). All other reagents were of the highest grade pos-
sible from standard commercial sources.
2.2. Preparation of synaptosomes and subcellular fractionation
All experiments were performed with a crude synaptosomal fraction
(P2) prepared from Sprague^Dawley 4^6-week-old rat brains, accord-
ing to [15], with slight modi¢cations [10]. In the cases where a sub-
cellular fractionation was required, the synaptosomes were collected
by centrifugation after each treatment and resuspended in 0.5 ml of
homogenization bu¡er, containing 20 mM Tris^HCl (pH 7.5), 2 mM
EDTA, 0.5 mM EGTA, 2 mM dithiothreitol, 1 mM Na3VO4, 50 mM
NaF, 2 mM PMSF, 10 Wg/ml leupeptin and 25 Wg/ml aprotinin, and
disrupted by sonication. The homogenate was centrifuged for 1 h at
100 000Ug to separate the soluble fraction (supernatant), from the
particulate fraction (precipitated). The precipitated fraction was fur-
ther resuspended to the original volume using homogenization bu¡er
supplemented with Triton X-100 (0.3%), and subsequently sonicated
and incubated for 1 h at 4‡C. The extract was centrifuged for 1 h at
100 000Ug and the resulting supernatant was considered as the par-
ticulate fraction extract. Protein concentration was determined ac-
cording to [16].
2.3. Immunoprecipitation and Western blot analysis
After treatment, synaptosomes were collected by centrifugation and
the reaction medium was eliminated. Next, 1 ml of homogenization
bu¡er supplemented with 0.3% Triton X-100 was added and the syn-
aptosomes were disrupted by sonication. For immunoprecipitation,
1 mg of total protein was incubated by gentle rocking at 4‡C over-
night in the presence of 4 Wg of antibody. The immunocomplex was
then captured by adding 100 Wl of washed Protein-A agarose bead
slurry (50 Wl of packed beads) previously incubated with 3% BSA/PBS
to eliminate unspeci¢c binding and gently rocked at 4‡C for 2 h. The
agarose beads were collected by pulsing and the supernatant was
drained o¡. The beads were washed three times with ice-cold PBS,
resuspended in 100 Wl 2Unon-reducing sample bu¡er and then boiled
for 4 min. Next, 10 Wl of each sample were analyzed in SDS^PAGE.
The separated proteins were transferred to a polyvinylidene £uoride
(PVDF) membrane. The blotting bu¡er used contained 48 mM Tris,
39 mM glycine, 1.3 mM SDS and 20% methanol (pH 8.3). The mem-
brane ¢lters were blocked for 1 h with PBS/4% BSA in the case of the
antibodies directed against phospho-amino acids, and with PBS/5%
defatted powdered milk in the rest of the cases. Next, the membranes
were incubated overnight with the corresponding antibody diluted in
blocking bu¡er. The polyclonal antibodies against the PKC isoforms
K, L and Q were purchased by Boehringer Mannheim GmbH (Mann-
heim, Germany). The speci¢c antibody against phosphotyrosine
(Clone PY99) was from Santa Cruz Biotechnology (CA, USA), and
phosphoserine (polyclonal antibody) was obtained from Zymed Lab-
oratories Inc. (San Francisco, CA, USA); the polyclonal antibody
against the SERT and the SERT antibody-control peptide (AG297)
were from Chemicon International (Temecula, CA, USA), and the
monoclonal antibody against PLCQ1 was from Upstate Biotechnology
(Lake Placid, NY, USA). Next, the membrane ¢lters were incubated
for 1 h with a secondary antibody conjugated with horseradish per-
oxidase diluted in blocking bu¡er. Several washes with PBS/0.05%
Tween 20 were performed between the steps. The Western blots
were developed with a bu¡er containing 0.1 M Tris^HCl pH 8.6,
0.2 mg/ml luminol, 0.01 mg/ml p-coumaric acid and 0.01% H2O2
and exposed to Amersham ECL ¢lms. The computer-assisted analysis
of the bands was performed with a Bio-Rad GS700 system, and data
were processed with a Bio-Rad Molecular Analyst image program
using a Dell work station. Repeated scans were taken for ¢lm non-
linearity corrections.
2.4. Determination of 3H-inositol phosphates and 3H-inositol lipids
Polyphosphoinositide hydrolysis was determined according to [17].
The crude synaptosomal fraction (P2) was labelled in bulk with myo-
[3H]inositol for 2 h at 37‡C, washed and transferred in 100 Wl aliquots
to tubes with 100 Wl of Krebs^Ringer bu¡er containing 10 mM LiCl
and, when appropriate, agonists. After 30 min, reactions were stopped
by adding 1.2 ml of chloroform:methanol (1:2). Samples of the aque-
ous phases (1 ml) were neutralized with 1.5 M NH4OH, diluted with
5 ml of water, and loaded onto columns with 0.5 ml of Dowex
AG1X8 (100^200 mesh, formate form). After washing the columns
with 6U4 ml of water and 2U4 ml of 60 mM sodium formate/5 mM
borax to remove [3H]inositol and [3H]glycerophosphorylinositol, 3H-
inositol phosphates were eluted together with 2U4 ml of 1.0 M am-
monium formate/0.1 M formic acid. After 12 ml of a toluene/Triton
X-100-based scintillation cocktail were added, vials were cooled to
form a clear homogeneous phase, and were then counted at a 30%
e⁄ciency rate. Accumulation of 3H-inositol phosphates was calculated
as the percentage of lipid labelling in the same sample, with total
[3H]inositol labelling of lipids monitored by counting 0.2-ml aliquots
of the organic phases. When agonist e¡ects on [3H]inositol labelling of
lipids were examined, synaptosomes were preincubated for 10 min
with agonists and lithium prior to the addition of [3H]inositol
(4 WCi/ml). To decrease the background, organic phases containing
3H-inositol lipids were washed with 1.5 ml of a new aqueous phase.
2.5. Assay of [3H]5-HT uptake
In the standard assay, to measure the synaptosomal 5-HT uptake,
100 Wl of synaptosomes, diluted with oxygenated Krebs^Ringer bicar-
bonate bu¡er to achieve a ¢nal protein concentration of 0.4^0.8
mg/ml, was mixed in a polypropylene tube with 50 Wl of toxin diluted
in Krebs^Ringer bicarbonate bu¡er containing 0.05% BSA, or with 50
Wl of the same medium without toxin as a control. After a preincubation
period of 30 min at 37‡C in a shaking water bath, uptake was started
by the addition of 50 Wl [3H]5-HT. For saturation experiments, the
Fig. 1. Apparent kinetics parameters of serotonin transport. The e¡ects of TeTx and TPA on [3H]5-HT uptake were evaluated by saturation
experiments and evaluated the kinetic parameters by bound/free versus bound analyses. Synaptosomal fractions were preincubated for 30 min
with saline (a), or in the left panel with TeTx (b, R), and in the right panel with TPA (8, F). Transport activity was measured using six dif-
ferent concentrations of [3H]5-HT (5^160 nM) for 5 min at 37‡C. Data are mean þ S.D. (bars) of a triplicate determination of a representative
experiment.
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tritiated amine concentration ranged from 5 to 160 nM. After an
incubation of 5 min at 37‡C, samples were ¢ltered in vacuum over
Whatman GF/C (Whatman International Ltd., Maidstone, UK) ¢lters
in a vacuum-¢ltration manifold (Brandel Inc., Gaithersburg, MD,
USA) and washed three times with 5 ml ice-cold Krebs^Ringer bicar-
bonate bu¡er. Filters were then dried, placed in vials with 5 ml bio-
degradable counting scintillante (Amersham Int. Plc, Buckingham-
shire, UK) and counted in a Wallac-1409 liquid scintillation
counter, with a counting e⁄ciency of 45%. Radioactivity accumulated
by synaptosomes at 0‡C for 5 min was routinely subtracted, and
temperature-dependent uptake was de¢ned as the di¡erence between
uptake carried out at 37‡C and at 0‡C.
3. Results
3.1. TeTx, like TPA, induces [3H]5-HT uptake inhibition in
rat-brain synaptosomes
The accumulation of [3H]5-HT into synaptosomal-enriched
P2 fractions was used to determine the kinetic parameters
of the SERT, and initial uptake velocity was measured at
[3H]5-HT concentrations that ranged from 5 to 160 nM
(Fig. 1). Kinetic analysis based on non-linear regression anal-
ysis revealed a [3H]5-HT uptake with an apparent Vmax =
404.8 þ 11.7 fmol/min/mg of protein and a KM = 48.4 þ 3.4
nM. Treatment with both TeTx and TPA signi¢cantly inhibit
the [3H]5-HT uptake. Signi¢cant decreases with respect to
control were found in apparent Vmax when the synaptosomes
were treated for 30 min at 37‡C with two concentrations of
the toxin, 1 nM TeTx (252.9 þ 7.3 fmol/min/mg) and 5 nM
TeTx (183.6 þ 8.7 fmol/min/mg), and with two concentrations
of the PKC activator, 1 WM TPA (295.0 þ 7.6 fmol/min/mg)
and 10 WM TPA (257.1 þ 7.0 fmol/min/mg). The values of P
were statistically signi¢cant (P6 0.01, n = 3). No signi¢cant
di¡erences were found among the KM of [3H]5-HT uptake
in all cases shown in Fig. 1. The results were evaluated by
the bound/free versus bound analysis (Eadie^Hofstee plots).
3.2. TeTx induces dose-dependent translocation of
PKC isoforms.
In order to examine the redistribution of PKC subspecies
after incubation with TeTx, immunodetection of isoforms
present in cytosol and in membranous fractions from synap-
tosomal preparations were assessed (Fig. 2). The three sub-
species of the cPKC family show response. The PKC-K is
slightly down-regulated (60% of the control in both fractions
at the maximum TeTx concentration tested, 300 nM), while
the PKC-L is clearly translocated at 5 nM TeTx, appearing
down-regulation at greater concentrations. The PKC-Q shows
the maximal translocation at 50 nM TeTx and is down-regu-
lated at 300 nM TeTx.
3.3. TeTx induces both PLC activation and PLCQ1
phosphorylation at Tyr residues via tyrosine kinase
receptors (TyrKRs)
Full evidence of PLC activation was obtained by measure-
ment of sustained inositol phosphates accumulation in the
tissues treated with the neurotoxin and with the endogenous
agonist of the TyrKRs trkA, NGF, and were compared with
the breakdown of phosphatidyl-3-inositol 4,5-diphosphates
(PIP2) mediated by muscarinic activation with carbachol.
TeTx stimulated the PIP2 hydrolysis in rat-brain synapto-
somes. The stimulation observed with TeTx (1 nM) was sim-
ilar to that obtained with the NGF (100 nM)-treated synap-
tosomes, 129 þ 30% and 139 þ 13%, respectively. Carbachol (1
mM) was more e¡ective in stimulating PIP2 hydrolysis,
230 þ 21% (Fig. 3A), probably due to the di¡erent PLC iso-
enzymes induced during each activation. Since it known that
NGF produces its action via activation/phosphorylation of a
PLCQ isoenzyme, this prompted our group to identify whether
TeTx produces speci¢c phosphorylation of PLCQ1 via some
TyrKRs. To determine the identity of this phosphorylated
Fig. 2. E¡ect of TeTx on the subcellular cPKC isoforms distribution. Aliquots of 1 ml from a synaptosomal fraction suspension were treated
with vehicle as control, and TeTx for 30 min at 30‡C. After treatment, the synaptosomes were collected by centrifugation and the cytosolic ‘a’
and particulate ‘b’ fractions separated, as indicated in Section 2. Thereafter, the samples from each fraction were electrophoresed in 10% acryl-
amide resolving gels, transferred to a PVDF membrane and probed separately with antibodies against PKC-K, -L, and -Q isoforms. The inten-
sity of the bands of each fraction was determined by scanning and expressed as a percentage, with respect to its control. The results are ex-
pressed as means þ S.D. of the percentage of three separate experiments and asterisks represent values signi¢cantly di¡erent from the control
group (P6 0.05). Insets: Representative gels of the subcellular redistribution of PKC isoforms.
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protein (Fig. 3B), the synaptosome lysate was immunopreci-
pitated using polyclonal antibodies directed against phospho-
tyrosine residues (Clone PY99) and blotted with anti-PLCQ1
antibody. The synaptosomes were treated with TeTx (1 nM)
or with NGF (50 nM) for 1, 10 or 30 min. Fig. 3B shows that
the elevation of protein phosphorylation of PLCQ1 was evi-
dent in both treatments at 1 min and they displayed maximal
phosphorylation by 10 min, which remained above the basal
level even after 30 min, as was observed by the increase of the
bands of 150 kDa.
3.4. TeTx, like TPA, induces protein phosphorylations in Ser
residues and speci¢c SERT phosphorylation
Induction of the Ser-phosphorylation by TeTx (1 nM) or by
TPA (100 nM) was compared with the basal phosphorylation
level present in the vehicle synaptosomes. As can be observed,
in Fig. 4A, the increase of general Ser-phosphorylation was
observed with respect to the control. Both treatments also
produce a speci¢c density increase of a band with a molecular
weight close to the SERT molecular weight (V76 kDa).
SERT is expressed equally in treated and untreated synapto-
somes, demonstrated by Western blot using anti-SERT anti-
body (data not shown). However, by prior immunoprecipita-
tion with anti-PSer antibody and probed with anti-SERT or
vice versa immunoprecipitation with anti-SERT antibody and
probed with anti-PSer antibody, an increase of density of the
bands corresponding to the molecular weight of SERT can be
seen (Fig. 4B). The synaptosomes were incubated for 30 min
at 37‡C with vehicle, TeTx (1 nM) or TPA (100 nM). The
incubation of membranes in Western blot experiments with
anti-SERT blocked with the antigenic peptide dramatically
abolished the band of 76 kDa corresponding to SERT (Fig.
5). On the other hand, the speci¢city of the anti-PSer antibody
Fig. 4. E¡ect of TeTx (1 nM) and TPA (100 nM) on SERT phosphorylation. A: Induction of Ser-phosphorylation, the arrowheads show the
Ser-phosphorylated proteins as consequence of the incubation with TeTx and TPA. B: The blot on the left corresponds to the immunoprecipi-
tations (IP) of the Ser-phosphorylated proteins with anti-PSer antibody, in response to TeTx or to TPA, and probed with anti-SERT antibody.
Meanwhile, the blot on the right corresponds to the IP of SERT with anti-SERT antibody and probed with anti-PSer antibody, in the same
conditions.
Fig. 3. A: Stimulation of PIP2 hydrolysis by carbachol, NGF and
TeTx. Synaptosomes relabelled with myo-[3H]inositol were incubated
in Krebs^Ringer bu¡er containing 10 mM LiCl with no further ad-
ditions (control), 1 mM carbachol, 100 nM NGF or with 1 nM
TeTx. The radioactivity detected in the control corresponded to
7.3 þ 1.2% of the total radioactivity. Data are expressed as
means þ S.D. Asterisks represent values signi¢cantly di¡erent form
the control group P6 0.01 (n = 4^7). B: Time course of TeTx and
NGF-induced PLCQ1 phosphorylation. Synaptosomes were incu-
bated at 30‡C with TeTx (1 nM) or NGF (50 nM). Equal amounts
of lysate from each timepoint, were immunoprecipitated with 4 Wg
of antibody (clone PY99) directed against PTyr residues, and blots
were probed with anti-PLCQ1 antibody.
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was assessed by blocking the PSer prior to membrane incuba-
tion treatment that induced diminution of the 76-kDa band
corresponding to SERT (results not shown).
3.5. Bisindolylmaleimide-1 (BIM-1) blocks the TeTx and TPA
induction of SERT phosphorylation
Western blot of immunoprecipitations demonstrated that
coapplication of TeTx (1 nM), or TPA (100 nM), in the pres-
ence of PKC-speci¢c inhibitor BIM-1, 5 WM) substantially
blunted the PKC-dependent SERT phosphorylation in rat-
brain synaptosomes (Fig. 6A). The quanti¢cation by densi-
tometry of the results obtained with a set of identical experi-
ments to the upper blot (n = 3^5) demonstrated the statistical
signi¢cance of the increase of SERT phosphorylation in the
tissue treated with TeTx or with TPA. The bands revealed a
two-fold stimulation of SERT phosphorylation after TeTx or
TPA application. This phosphorylation was abolished by co-
incubation with BIM-1. In Fig. 6, a clear and signi¢cant re-
duction of the basal PKC-dependent SERT phosphorylation
in control synaptosomes treated with BIM-1 can also be ob-
served. Like activation/phosphorylation of PLCQ1, SERT
phosphorylation occurs over a brief period of time and it
reaches at the maximal band density after 10 min of treat-
ment, which remained above the basal level even after 30 min,
as was observed by the increase of the density bands of 76
kDa, presented in Fig. 7.
4. Discussion
Serotonin is a neurotransmitter in the CNS and PNS which
modulates a wide spectrum of behaviors. Serotonin is also
present in other tissues, including platelets, where it represents
a major secretory product of activated cells [18]. The action of
5-HT, and other neurotransmitters, in these tissues is termi-
nated by active transport [19], and a single gene product en-
coding the SERT appears to be the sole gene responsible for
extracellular 5-HT clearance [20,21]. Acute and long-term reg-
ulations of serotonin transport have been extensively studied
[22], and SERT gene expression is, in general, positively regu-
lated by hormones and growth factors. Some other transduc-
tion mechanisms have been implicated in acute regulation of
expressed SERT, and PKC has been implicated in the inhibi-
tion and down-regulation of this type of transporters [23,24].
Fig. 5. Blocking of the speci¢c immunoreactive band observed with
anti-SERT with the antigenic peptide. Synaptosomes were incubated
with 100 nM TPA for 30 min at 30‡C. Subsequently, the immuno-
precipitation was performed as described in Section 2, using 4 Wg of
antibody directed against PSer, and blots were probed with anti-
SERT antibody with or without being previously blocked with the
SERT control peptide, corresponding to a 15-amino acid sequence
between transmembrane domains 7 and 8 of the rat SERT.
Fig. 6. A: Inhibition of TPA and TeTx-induced SERT phosphoryla-
tion by the PKC inhibitor BIM-1. Synaptosomes were incubated
with BIM-1 or with vehicle for 30 min at 30‡C. Next, TPA, TeTx
or vehicle were added and incubated for 30 additional min at 30‡C.
Subsequently, the immunoprecipitation was performed as described
in Section 2, using 4 Wg of antibody directed against SERT, and
blots were probed with anti-PSer antibody. B: Quanti¢cation by
densitometry of the results obtained in A. The results are expressed
as means þ S.D. of the percentage of 3^5 separate experiments, and
asterisks represent values signi¢cantly di¡erent (P6 0.05) from the
control group.
Fig. 7. Time-course of TeTx-induced SERT phosphorylation. Synap-
tosomes were incubated at 30‡C with TeTx (1 nM) for 1, 10 or
with TPA (100 nM) for 30 min. Equal amounts of lysate from each
timepoint, obtained by sonication and with a protein concentration
of 1 mg/ml, were immunoprecipitated with 4 Wg of antibody di-
rected against phosphoserine residues, and blots were probed with
anti-SERT antibody.
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In Fig. 1, the [3H]5-HT uptake inhibition induced by both
TeTx and TPA is represented. The inhibitory e¡ect by TPA
can be observed a low concentrations, 1^10 WM for 30 min,
and produces a decrease in transport capacity (30^40%) with
no change for the apparent a⁄nity to serotonin (KM) in rat-
brain synaptosomes; these results are similar to those pre-
sented by Anderson and coworkers [25] and by our group
(data not shown) in primary neuronal cultures. But the e¡ects
of TeTx, and its similitude, modifying the kinetic parameters
of 5-HT inhibition with respect to TPA have been introduced
here. Nevertheless, TeTx was three orders of magnitude more
potent than TPA in producing a decrease in transport ca-
pacity (Vmax); in our tissue concentrations of 1^5 nM of
TeTx for 30 min, it produces a decrease in Vmax of around
40^50%. The data corroborate prior characterization of TeTx
as an inhibitor of the Na-dependent serotonin uptake [10,11]
and open the possibility of inferring the transduction mecha-
nism modulated by the toxin.
PKC is speci¢cally activated and down-regulated by the
phorbol ester TPA [26] and by TeTx [27]. We must consider
that the enzymatic assay re£ects the sum of all Ca2- and
phospholipid-dependent protein kinases; therefore, to obtain
more information, work with speci¢c PKC isoforms must be
done. In the present work, the Western blots showed a loss of
immunoreactivity of the soluble fraction, due to TeTx, in the
cPKC (K, L and Q) isoforms. The particulate fractions showed
a loss of immunoreactivity of the PKC-K and an increase of
PKC-L and -Q with a tendency to total (soluble and particu-
late) down-regulation common to the three isoforms (Fig. 2).
These results are very close to those previously presented by
Gil and coworkers [28,29] with NGF (1^100 nM) and TeTx
(1^100 nM), with respect to the cPKC subspecies, and di¡er
from those obtained under the same conditions with TPA (5^
1000 nM). TPA was more e¡ective to down-regulate both
soluble and particulate fractions. The di¡erences would be
due to the interaction of TeTx and NGF with some receptors
which promote the activation of PLC, in comparison to the
vis-a'-vis interaction between TPA and PKC.
In Fig. 3A, stimulation of PIP2 hydrolysis by carbachol,
NGF and TeTx was performed to investigate the last pro-
posal. Although the accumulation of [3H]inositol phosphates
due to the action of TeTx and NGF is relatively modest
compared to the synaptosomes treated with carbachol, the
responses are signi¢cant and probably the activation of only
one type of PLC, i.e., PLCQ is involved. Western blot for
immunoprecipitation with anti-PTyr and probed with anti-
PLCQ1 antibodies make the presence of a connection between
PLCQ1 and PKC manifest. TeTx (1 nM) as well as NGF (50
nM) mediate a fast and speci¢c Tyr-phosphorylation of the
PLCQ1.
The receptor-dependent activation/phosphorylation of
PLCQ1 is responsible for the speci¢c activation (translocation)
of some PKC isoforms, and the activated PKC could be re-
sponsible for the increase of phosphoproteins found after
treatment with TeTx or with TPA, (data obtained by Western
blot with anti-PSer antibody (Fig. 4A)). Activation of PKC
results in a loss of transport capacity as a consequence of
phosphorylation of multiple members of the Na/Cl3-coupled
neurotransmitter transporters [14,22,30,31]. We present the
coincidence among activation/phosphorylation of PLCQ1, ac-
tivation (translocation) of cPKC isoforms, and non-competi-
tive serotonin transport inhibition (a decrease in transport
capacity, Vmax, rather than changes in substrate a⁄nity, KM,
was observed). In Figs. 4B, 6 and 7, it has been demonstrated
that one phosphoprotein obtained as a consequence of TeTx
treatment is SERT; it could be signi¢cantly phosphorylated,
with respect to the basal phosphorylation, after treatment
with low doses of TeTx or with moderate doses of TPA.
There is no evidence of sequestration of SERT after phos-
phorylation, as has been demonstrated by other authors
[32]. Phosphorylation of the SERT is demonstrated by a set
of elegant experiments which play with the speci¢city of two
antibodies with a⁄nity to the SERT. This set of antibodies
could substitute the use of radioactivity experiments with
[32P]orthophosphate with similar e⁄ciency. Finally, that
SERT phosphorylation produced by both, TeTx and TPA,
could be e⁄ciently prevented with the speci¢c PKC inhibitor
BIM-1 is demonstrated. PLC activation leads to PKC activa-
tion and then leads to SERT phosphorylation; however, it is
not possible to conclude from our results that phosphoryla-
tion and reduction of serotonin uptake are directly produced
by PKC, since other targets of PKC could contribute to the
¢nal e¡ect.
Recently Gil and coworkers [29] presented convincing data
demonstrating that TeTx activates signal transduction path-
ways involving trkA, PLCQ1, and PKC isoforms. The ¢nal
conclusions of these studies are that part of the action of
TeTx consists of modifying the signal cascade initiated in
some TyrKRs on nerve tissue previous to their cellular inter-
nalization, modifying the activity of a PLC isoform, cPKC
distribution (activation) and, ¢nally, a¡ecting SERT phos-
phorylation and serotonin transport capacity.
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